{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:18:50Z","timestamp":1790691530309,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,6,8]]},"DOI":"10.1038\/onc.2016.478","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T12:24:06Z","timestamp":1483964646000},"page":"3300-3311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera"],"prefix":"10.1038","volume":"36","author":[{"given":"T","family":"Tsuruta-Kishino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"key":"BFonc2016478_CR1","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.","journal-title":"PLoS Med"},{"key":"BFonc2016478_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144\u20131148.","journal-title":"Nature"},{"key":"BFonc2016478_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387\u2013397.","journal-title":"Cancer Cell"},{"key":"BFonc2016478_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u20131061.","journal-title":"Lancet"},{"key":"BFonc2016478_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779\u20131790.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR8","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452\u20132466.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","volume":"108","author":"C Lacout","year":"2006","unstructured":"Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652\u20131660.","journal-title":"Blood"},{"key":"BFonc2016478_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584\u2013596.","journal-title":"Cancer Cell"},{"key":"BFonc2016478_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","volume":"120","author":"A Mullally","year":"2012","unstructured":"Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL . Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood 2012; 120: 166\u2013172.","journal-title":"Blood"},{"key":"BFonc2016478_CR12","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"G Wernig","year":"2006","unstructured":"Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG . Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274\u20134281.","journal-title":"Blood"},{"key":"BFonc2016478_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","volume":"116","author":"C Marty","year":"2010","unstructured":"Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010; 116: 783\u2013787.","journal-title":"Blood"},{"key":"BFonc2016478_CR14","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","volume":"121","author":"JA Kennedy","year":"2013","unstructured":"Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013; 121: 2725\u20132733.","journal-title":"Blood"},{"key":"BFonc2016478_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","volume":"70","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447\u2013452.","journal-title":"Cancer Res"},{"key":"BFonc2016478_CR16","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119: 4480\u20134485.","journal-title":"Blood"},{"key":"BFonc2016478_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R . p53 lesions in leukemic transformation. N Engl J Med 2011; 364: 488\u2013490.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2162-3619-1-15","volume":"1","author":"W Zhao","year":"2012","unstructured":"Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ . JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol 2012; 1: 15.","journal-title":"Exp Hematol Oncol"},{"key":"BFonc2016478_CR19","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E, Bareford D et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115: 2891\u20132900.","journal-title":"Blood"},{"key":"BFonc2016478_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/humu.10190","volume":"21","author":"S Peller","year":"2003","unstructured":"Peller S, Rotter V . TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21: 277\u2013284.","journal-title":"Hum Mutat"},{"key":"BFonc2016478_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1101\/gad.1940710","volume":"24","author":"Z Zhao","year":"2010","unstructured":"Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24: 1389\u20131402.","journal-title":"Genes Dev"},{"key":"BFonc2016478_CR22","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/blood-2012-05-356014","volume":"120","author":"V Pant","year":"2012","unstructured":"Pant V, Quintas-Cardama A, Lozano G . The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 2012; 120: 5118\u20135127.","journal-title":"Blood"},{"key":"BFonc2016478_CR23","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P . TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFonc2016478_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/356215a0","volume":"356","author":"LA Donehower","year":"1992","unstructured":"Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215\u2013221.","journal-title":"Nature"},{"key":"BFonc2016478_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nm.2063","volume":"16","author":"JL Barlow","year":"2010","unstructured":"Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16: 59\u201366.","journal-title":"Nat Med"},{"key":"BFonc2016478_CR26","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1182\/blood-2012-01-405332","volume":"120","author":"H Xu","year":"2012","unstructured":"Xu H, Menendez S, Schlegelberger B, Bae N, Aplan PD, Gohring G et al. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model. Blood 2012; 120: 3089\u20133097.","journal-title":"Blood"},{"key":"BFonc2016478_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V100.1.238","volume":"100","author":"SC Kogan","year":"2002","unstructured":"Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002; 100: 238\u2013245.","journal-title":"Blood"},{"key":"BFonc2016478_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.278.5340.1059","volume":"278","author":"AT Look","year":"1997","unstructured":"Look AT . Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059\u20131064.","journal-title":"Science"},{"key":"BFonc2016478_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.genet.32.1.495","volume":"32","author":"JD Rowley","year":"1998","unstructured":"Rowley JD . The critical role of chromosome translocations in human leukemias. Annu Rev Genet 1998; 32: 495\u2013519.","journal-title":"Annu Rev Genet"},{"key":"BFonc2016478_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.molmed.2004.08.005","volume":"10","author":"JL Hess","year":"2004","unstructured":"Hess JL . MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 2004; 10: 500\u2013507.","journal-title":"Trends Mol Med"},{"key":"BFonc2016478_CR31","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1101\/gad.1143403","volume":"17","author":"A Cozzio","year":"2003","unstructured":"Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL . Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029\u20133035.","journal-title":"Genes Dev"},{"key":"BFonc2016478_CR32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nature03485","volume":"434","author":"VG Gorgoulis","year":"2005","unstructured":"Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907\u2013913.","journal-title":"Nature"},{"key":"BFonc2016478_CR33","first-page":"603","volume":"10","author":"DM Shin","year":"2001","unstructured":"Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Preve 2001; 10: 603\u2013609.","journal-title":"Cancer Epidemiol Biomarkers Preve"},{"key":"BFonc2016478_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787\u2013798.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFonc2016478_CR36","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2011.313","volume":"31","author":"M Nakatake","year":"2012","unstructured":"Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012; 31: 1323\u20131333.","journal-title":"Oncogene"},{"key":"BFonc2016478_CR37","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111: E5401\u2013E5410.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016478_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.stem.2012.01.004","volume":"10","author":"Jr Gibbs KD","year":"2012","unstructured":"Gibbs Jr KD, Jager A, Crespo O, Goltsev Y, Trejo A, Richard CE et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 2012; 10: 210\u2013217.","journal-title":"Cell Stem Cell"},{"key":"BFonc2016478_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138\u2013152.","journal-title":"Cancer Cell"},{"key":"BFonc2016478_CR40","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI41495","volume":"121","author":"JE Sarry","year":"2011","unstructured":"Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2Rgammac-deficient mice. J Clin Invest 2011; 121: 384\u2013395.","journal-title":"J Clin Invest"},{"key":"BFonc2016478_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stem.2008.11.006","volume":"4","author":"Y Liu","year":"2009","unstructured":"Liu Y, Elf SE, Miyata Y, Sashida G, Huang G, Di Giandomenico S et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4: 37\u201348.","journal-title":"Cell Stem Cell"},{"key":"BFonc2016478_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0301-472X(03)00072-9","volume":"31","author":"M TeKippe","year":"2003","unstructured":"TeKippe M, Harrison DE, Chen J . Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 2003; 31: 521\u2013527.","journal-title":"Exp Hematol"},{"key":"BFonc2016478_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature06869","volume":"453","author":"OO Akala","year":"2008","unstructured":"Akala OO, Park IK, Qian D, Pihalja M, Becker MW, Clarke MF . Long-term haematopoietic reconstitution by Trp53-\/-p16Ink4a-\/-p19Arf-\/- multipotent progenitors. Nature 2008; 453: 228\u2013232.","journal-title":"Nature"},{"key":"BFonc2016478_CR44","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.exphem.2008.04.012","volume":"36","author":"J Chen","year":"2008","unstructured":"Chen J, Ellison FM, Keyvanfar K, Omokaro SO, Desierto MJ, Eckhaus MA et al. Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol 2008; 36: 1236\u20131243.","journal-title":"Exp Hematol"},{"key":"BFonc2016478_CR45","doi-asserted-by":"publisher","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","volume":"2","author":"M Oren","year":"2010","unstructured":"Oren M, Rotter V . Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFonc2016478_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5581\/1516-8484.20110116","volume":"33","author":"LC Dos Santos","year":"2011","unstructured":"Dos Santos LC, Ribeiro JC, Silva NP, Cerutti J, da Silva MR, Chauffaille Mde L . Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Revista Brasileira de Hematologia e Hemoterapia 2011; 33: 417\u2013424.","journal-title":"Revista Brasileira de Hematologia e Hemoterapia"},{"key":"BFonc2016478_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1158\/1078-0432.CCR-12-2087","volume":"19","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F . The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Research 2013; 19: 327\u2013335.","journal-title":"Clin Cancer Research"},{"key":"BFonc2016478_CR48","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","volume":"110","author":"D Haase","year":"2007","unstructured":"Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385\u20134395.","journal-title":"Blood"},{"key":"BFonc2016478_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1947601911408076","volume":"2","author":"CC Kumar","year":"2011","unstructured":"Kumar CC . Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011; 2: 95\u2013107.","journal-title":"Genes Cancer"},{"key":"BFonc2016478_CR50","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1073\/pnas.0508143103","volume":"103","author":"K Wagner","year":"2006","unstructured":"Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr\/abl-induced malignancy. Proc Natl Acad Sci USA 2006; 103: 6338\u20136343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016478_CR51","volume-title":"JAKAVI Tablets 5\u2009mg Interview Form","author":"NP KK","year":"2015","unstructured":"KK NP . JAKAVI Tablets 5\u2009mg Interview Form In Agency PMDA, editor: Japan, 2015."},{"key":"BFonc2016478_CR52","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","volume":"119","author":"A Tefferi","year":"2012","unstructured":"Tefferi A . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012; 119: 2721\u20132730.","journal-title":"Blood"},{"key":"BFonc2016478_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.beha.2012.10.003","volume":"25","author":"S Pei","year":"2012","unstructured":"Pei S, Jordan CT . How close are we to targeting the leukemia stem cell? Best Pract Res Clin Haematol 2012; 25: 415\u2013418.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFonc2016478_CR54","doi-asserted-by":"publisher","first-page":"17ra19","DOI":"10.1126\/scitranslmed.3000349","volume":"2","author":"Y Saito","year":"2010","unstructured":"Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010; 2: 17ra19.","journal-title":"Sci Transl Med"},{"key":"BFonc2016478_CR55","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/stem.1678","volume":"32","author":"F Pellicano","year":"2014","unstructured":"Pellicano F, Mukherjee L, Holyoake TL . Cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells 2014; 32: 1373\u20131379.","journal-title":"Stem Cells"},{"key":"BFonc2016478_CR56","first-page":"3313","volume":"8","author":"T Tsukada","year":"1993","unstructured":"Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 1993; 8: 3313\u20133322.","journal-title":"Oncogene"},{"key":"BFonc2016478_CR57","first-page":"485","volume":"25","author":"C Nam","year":"2010","unstructured":"Nam C, Doi K, Nakayama H . Etoposide induces G2\/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM\/p53-related pathway. Histol Histopathol 2010; 25: 485\u2013493.","journal-title":"Histol Histopathol"},{"key":"BFonc2016478_CR58","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1101\/gad.14.8.994","volume":"14","author":"S Marino","year":"2000","unstructured":"Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A . Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000; 14: 994\u20131004.","journal-title":"Genes Dev"},{"key":"BFonc2016478_CR59","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.7660125","volume":"269","author":"R Kuhn","year":"1995","unstructured":"Kuhn R, Schwenk F, Aguet M, Rajewsky K . Inducible gene targeting in mice. Science 1995; 269: 1427\u20131429.","journal-title":"Science"},{"key":"BFonc2016478_CR60","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1038\/onc.2009.288","volume":"28","author":"M Shimabe","year":"2009","unstructured":"Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y et al. Pbx1 is a downstream target of Evi-1 in hematopoietic stem\/progenitors and leukemic cells. Oncogene 2009; 28: 4364\u20134374.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2016478","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2016.478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:11:12Z","timestamp":1647879072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":60,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,6,8]]}},"alternative-id":["BFonc2016478"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.478","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727188266.793564984","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]},"assertion":[{"value":"8 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}